- |||||||||| moxifloxacin intravenous / Generic mfg.
PK/PD data, Preclinical, Journal: Codetermination of antimicrobial agents in rabbit tear fluid using LC-MS/MS assay: Insights into ocular pharmacokinetic study. (Pubmed Central) - May 10, 2024
For diseases with atypical symptoms or difficulty in determining the pathogens, mNGS is suggested in clinical procedures for rapid and accurate diagnosis and treatment. Managing ocular microbial infections typically requires pharmacotherapy using antibiotic eye drops, such as moxifloxacin hydrochloride (MFX), combined with an antifungal agent like amphotericin B (AB)...The approach was strictly validated, encompassing tests of selectivity, linearity (with r2
- |||||||||| levofloxacin / Generic mfg., moxifloxacin intravenous / Generic mfg.
Journal: Xpert MTB/XDR assay: rapid TB drug resistance detection. (Pubmed Central) - May 6, 2024
The Index test exhibited promising outcomes in identifying resistance to isoniazid and fluoroquinolones, surpassing the performance of the LPA. This could be valuable for promptly initiating treatment in cases of drug-resistant tuberculosis.
- |||||||||| Preclinical, Journal: Results from a Joined Prospective Study to Evaluate the Sensitivity of the In Vivo Dog QT Assay in Line with the ICH E14/S7B Q&A Best Practices. (Pubmed Central) - May 6, 2024
By-timepoint analysis showed QTc prolongation induced by moxifloxacin, dofetilide, dolasetron, ondansetron, and quinine within human relevant plasma exposures ranges...As expected, levocetirizine showed no statistically significant effect on QTc across a range of exposure, well exceeding the therapeutic Cmax...Finally, concentration-QTc modeling enabled to predict the minimal plasma concentration needed to detect a 10?milliseconds QTc prolongation, including for quinine. The comparison with clinical available data supported the relevance of dogs under these experimental conditions as a robust translational predictor of drug-induced QTc prolongation in humans as a key pillar of the integrated risk assessment.
- |||||||||| Gatiflox (gatifloxacin) / Orient Europharma
Review, Journal, Adverse events: Association Between Fluoroquinolones and Major Adverse Cardiovascular Events: A Systematic Review. (Pubmed Central) - Apr 30, 2024
This systematic review emphasizes the need for cautious administration of FQs, particularly in patients with a preexisting cardiovascular condition. Routine cardiac monitoring using electrocardiograms is warranted for patients on high doses of FQs to preemptively detect the development of MACE, particularly arrhythmias.
- |||||||||| levofloxacin / Generic mfg., moxifloxacin intravenous / Generic mfg.
Preclinical, Journal: In vitro and ex vivo activity of the fluoroquinolone DC-159a against mycobacteria. (Pubmed Central) - Apr 29, 2024
Besides, it was more active than MOX/LX. Moreover, no cross-resistance was evidenced between DC-159a and LX/MOX as DC-159a could inhibit Mtb and MAC strains that were already resistant to LX/MOX.DC-159a could be a possible candidate in new therapeutic regimens for MDR/ XDR-TB and mycobacterioses cases.
- |||||||||| moxifloxacin intravenous / Generic mfg.
Journal: Moxifloxacin treatment for Mycoplasma hominis meningitis in an extremely preterm infant (Pubmed Central) - Apr 25, 2024
After treatment, the patient's cerebrospinal fluid tests returned to normal, and he was discharged as cured on the 76th day after birth. This article focuses on the diagnosis and treatment of neonatal Mycoplasma hominis purulent meningitis, introducing the multidisciplinary diagnosis and treatment of the condition in extremely preterm infants.
- |||||||||| pretomanid (PA-824) / Global Alliance for TB Drug Development, Lamprene (clofazimine) / Novartis, Sirturo (bedaquiline) / J&J, Pharmstandard
Trial completion, Enrollment change, HEOR: PRACTECAL-PRO: Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial (clinicaltrials.gov) - Apr 22, 2024
P=N/A, N=137, Completed,
We observed a worryingly high prevalence of AZM resistance mutations; however, empiric AZM treatment cleared twice as many MG infections as expected. Recruiting --> Completed | N=54 --> 137
- |||||||||| pretomanid (PA-824) / Global Alliance for TB Drug Development, Lamprene (clofazimine) / Novartis, Sirturo (bedaquiline) / J&J, Pharmstandard
Trial completion, Enrollment change, HEOR: PRACTECAL-EE: Economic Evaluation of New MDR TB Regimens (clinicaltrials.gov) - Apr 22, 2024
P2/3, N=73, Completed,
Recruiting --> Completed | N=54 --> 137 Recruiting --> Completed | N=200 --> 73
- |||||||||| moxifloxacin intravenous / Generic mfg.
Journal: Experience With Four-Month Rifapentine and Moxifloxacin-Based Tuberculosis Treatment in San Francisco. (Pubmed Central) - Apr 18, 2024
Our experience, with half of patients to date prematurely discontinuing HPMZ, illustrates the challenge of extrapolating findings from TB clinical trials commonly conducted in high-incidence, non-US settings to US clinical practice. Further experience may help identify best practices for implementing HPMZ, including identifying predictors of which patients may be most likely to benefit from and tolerate this regimen.
- |||||||||| azithromycin / Generic mfg., moxifloxacin intravenous / Generic mfg.
Journal: Mycoplasmoides genitalium Macrolide Resistance Detection is Needed in University Settings. (Pubmed Central) - Apr 17, 2024
For students treated with azithromycin, 30.3% generated a negative M. genitalium result upon follow-up, with 1g daily and 2-day 500mg dosing regimens demonstrating less efficacy than a 4-day 250mg regimen or moxifloxacin. Data indicate a need for molecular M. genitalium macrolide resistance determination from primary specimens in the university setting.
- |||||||||| Lamprene (clofazimine) / Novartis
Journal: T-wave morphology abnormalities in the STREAM stage 1 trial. (Pubmed Central) - Apr 8, 2024
P3
STREAM Stage 1 was a randomized controlled trial in rifampicin-resistant TB, comparing short and long regimens...QT/QTcF prolongation (?500?ms or increase in??60?ms from baseline) was more common on the short regimen which contained high-dose moxifloxacin and clofazimine...The trial is registered at ClinicalTrials.gov (CT.gov identifier: NCT02409290). Current Controlled Trial number, ISRCTN78372190.
- |||||||||| moxifloxacin intravenous / Generic mfg.
Preclinical, Journal: Continuous evaluation of single-dose moxifloxacin concentrations in brain extracellular fluid, cerebrospinal fluid, and plasma: a novel porcine model. (Pubmed Central) - Apr 4, 2024
pneumoniae strains are susceptible to vancomycin, linezolid, ertapenem, levofloxacin, moxifloxacin, rifampicin, and chloramphenicol. A single dose of weight-adjusted moxifloxacin administered intravenously did not achieve adequate target site concentrations within the uninflamed porcine brain ECF and CSF to reach the applied TB CNS target.
- |||||||||| Journal: Advances in antibiotic therapy for tuberculosis (Pubmed Central) - Apr 2, 2024
Additionally, considering the extent of anatomical involvement and bacterial burden allows for strategies that involve variable treatment durations based on the severity of the disease. The new tuberculosis treatments thus appear to be shorter and more personalized.
- |||||||||| Avastin (bevacizumab) / Roche, Sirturo (bedaquiline) / J&J, Pharmstandard
Preclinical, Journal: Normalizing granuloma vasculature and matrix improves drug delivery and reduces bacterial burden in tuberculosis-infected rabbits. (Pubmed Central) - Mar 30, 2024
RNA sequencing analysis of HDT-treated lung and granuloma tissues implicates up-regulated antimicrobial peptide and proinflammatory gene expression by ciliated epithelial airway cells as a putative mechanism of the observed antitubercular benefits in the absence of chemotherapy. These findings demonstrate that bevacizumab and losartan are well-tolerated stroma-targeting HDTs, normalize the granuloma microenvironment, and improve TB outcomes, providing the rationale to clinically test this combination in TB patients.
- |||||||||| moxifloxacin intravenous / Generic mfg.
Journal: Bacteria-Targeting Nanoparticles with ROS-Responsive Antibiotic Release to Eradicate Biofilms and Drug-Resistant Bacteria in Endophthalmitis. (Pubmed Central) - Mar 30, 2024
This study developed a novel antibiotic nanoparticle delivery system (MXF@UiO-UBI-PEGTK), which is composed of (i) moxifloxacin (MXF)-loaded UiO-66 nanoparticle as the core, (ii) bacteria-targeting peptide ubiquicidin (UBI29-41) immobilized on UiO-66, and (iii) ROS-responsive poly (ethylene glycol)-thioketal (PEG-TK) as the surface shell...Moreover, MXF@UiO-UBI-PEGTK demonstrated outstanding efficacy in treating bacterial endophthalmitis in vivo. This novel nanoparticle delivery system with ROS-responsive and bacteria-targeted properties promotes the precise and effective release of drugs and has significant potential for clinical application of treating bacterial endophthalmitis.
- |||||||||| moxifloxacin intravenous / Generic mfg.
Review, Journal: Imaging assessment of conjunctival goblet cells in dry eye disease. (Pubmed Central) - Mar 30, 2024
This article presents a comprehensive overview of both the structure and function of CGCs and their alterations in the context of DED, as well as current methods of CGCs imaging assessment. Additionally, potential directions for the visual evaluation of CGCs are discussed.
- |||||||||| Invanz (ertapenem) / Merck (MSD)
Journal: First Report and Characterization of a Plasmid-Encoded blaSFO-1 in a Multi-Drug-Resistant Aeromonas hydrophila Clinical Isolate. (Pubmed Central) - Mar 28, 2024
This is the first report of beta-lactamase SFO-1 within a clinical strain of Aeromonas. Due to the remarkable sequence identity of pMAH4 to plasmids associated with Enterobacterales genera like Klebsiella and the extensive capabilities of Aeromonas for horizontal gene transfer, our identification of a clinical isolate encoding SFO-1 on a plasmid suggests antibiotic resistance gene mobility between Enterobacterales and non-Enterobacterales species.
- |||||||||| Reimbursement, US reimbursement, Journal, Medicaid: Decreases and Pronounced Geographic Variability in Antibiotic Prescribing in Medicaid. (Pubmed Central) - Mar 25, 2024
This study identified sizable disparities by geography in the prescribing rates of eight antibiotics with over three-fold state-level differences. Areas with high prescribing rates, particularly for outpatients, may benefit from stewardship programs to reduce potentially unnecessary prescribing.
- |||||||||| moxifloxacin intravenous / Generic mfg.
Journal: Comparison Between Moxifloxacin and Chloramphenicol for the Treatment of Bacterial Eye Infections. (Pubmed Central) - Mar 21, 2024
Moreover, moxifloxacin showed higher activity compared with chloramphenicol in the inhibition of biofilm formation and in the disruption of biofilm, especially against S epidermidis biofilm. The lower corneal cell toxicity and the broader spectrum of antibacterial activity observed with moxifloxacin suggests its use in ophthalmic solution for the treatment of bacterial eye infections.
- |||||||||| moxifloxacin intravenous / Generic mfg.
Machine Learning Optimization: Defining Exposome-Metabolome Associated Aerodigestive Disease (San Diego Convention Center, Area C (Hall A-B2, Ground Level)) - Mar 17, 2024 - Abstract #ATS2024ATS_9222;
Acetaminophen and moxifloxacin were key exposures in GERD and BE, respectively...Transient receptor potential(TRP)V1 gene expression is altered in esophageal mucosa of reflux patients and TRPV1 is an acetaminophen target. Metabolic profiling provides a contemporaneous snapshot of an organism
- |||||||||| moxifloxacin intravenous / Generic mfg.
Antibiotic and antifungal drug-impregnated contact lenses via supercritical carbon dioxide for the treatment of keratitis (In-person; Galerie 1 (New Orleans Marriott)) - Mar 12, 2024 - Abstract #ACSSp2024ACS_Sp_11618;
Therefore, moxifloxacin (MOX) as an antibiotic and Amphotericin B (AMB) as an antifungal drug were loaded into contact lenses through drug adsorption and ScCO 2 impregnation techniques...Furthermore, the potential use of MOX and AMB-loaded contact lenses in the treatment of P. auruginosa and F. solani -induced keratitis in rabbits was investigated by in vivo analysis. Thus, contact lenses that can be used in the treatment of keratitis were developed by preparing antibiotics, and antifungal drug-loaded contact lenses employing the ScCO 2 technique may offer superior and highly effective dosage formulation for appropriate and desired release kinetics.
- |||||||||| moxifloxacin intravenous / Generic mfg.
Enhanced delivery of antibiotics using outer membrane vesicles | Poster Board #815 (In-person; Poster Board #815; Hall C (Ernest N. Morial Convention Center)) - Mar 12, 2024 - Abstract #ACSSp2024ACS_Sp_9266;
Specifically, when faced with clinical isolates of P. aeruginosa and S. aureus resistant to moxifloxacin , the antibiotics encapsulated in the outer membrane vesicles were much more effective. As we advance our research, future investigations will focus on identifying alternative antibiotics that display more effectiveness against gram-negative bacteria when encapsulated by outer membrane vesicles.
- |||||||||| pretomanid (PA-824) / Global Alliance for TB Drug Development, Sirturo (bedaquiline) / J&J, Pharmstandard
Journal: Drug-resistant tuberculosis is a global cause of concern. (Pubmed Central) - Mar 10, 2024
However, emerging resistance against bedaquiline and pretomanid, among other factors, persists as ongoing concerns in the global fight against DR-TB. While the new regimens are groundbreaking, the sustained development of novel drugs targeting the most resistant forms of tuberculosis is of utmost importance for future efforts against DR-TB.
|
